Chris Mason, MD, PhD, FRSB, FRCS, FMedSci
Chris Mason is Founder and CSO at AVROBIO, Inc. a clinical-stage, gene therapy company [NASDAQ AVRO]. He is a clinician-scientist with 30 years of cell and gene therapy experience spanning R&D, clinical medicine, and bioprocessing. He is a Full Professor of Cell and Gene Therapy in the Advanced Centre for Biochemical Engineering, University College London. In 2019, he was elected as a Fellow of The Academy of Medical Sciences. He is also a Founder and Board Director of OriBiotech Ltd., a company focused on next-generation fully-automated cell therapy bioprocessing, and Board Director of Krystal Biotech, Inc. [NASDAQ KRYS]. Dr. Mason was instrumental in the founding of the Alliance for Regenerative Medicine (ARM), the UK-Israel Science Council, and the London Regenerative Medicine Network. He is on the SAB of several companies and the UK Cell & Gene Therapy Catapult, and the Canadian Centre for the Commercialization of Regenerative Medicine (CCRM). Dr. Mason is Senior Editor of the journals Cell and Gene Therapy Insights and Regenerative Medicine.